In addition, 50 % of evaluable patients experienced shrinkage of untreated distal (abscopal) lesion. (immunedesign.com)
Among an additional 11 evaluable patients who did not have the T790M mutation, four had a confirmed response to the treatment (overall response rate of 36 %) and this group of patients had a median progression - free survival of 7.5 months. (sciencedaily.com)
The 11 evaluable patients enrolled in the brain cancer safety trial received three infusions of vitamin C a week for 2 months followed by two infusions per week for 7 months while receiving standard care radiation and chemotherapy. (sciencedaily.com)